Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · Zanubrutinib monotherapy (continuous, ALPINE-style)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | REG-ZANUBRUTINIB-CONTINUOUS |
| ID | IND-CLL-1L-ZANUBRUTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CLL |
| Sources | SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Co-Lead sign-off. Standard track for CLL 1L — alternative to existing IND-CLL-1L-BTKI (acalabrutinib). Both second-generation BTKis preferred over ibrutinib. Engine should treat both as interchangeable Cat 1 preferred options based on access. UA reimbursement gap: ibrutinib reimbursed but inferior cardiac profile; zanubrutinib + acalabrutinib not reimbursed.
Used By
Algorithms
ALGO-CLL-1L- ALGO-CLL-1LALGO-CLL-2L- ALGO-CLL-2L
Indication
IND-CLL-1L-BTKI- IND-CLL-1L-BTKI